172@29@17@137!~!172@29@0@53!~!|news|ipcalabs|management-interviews-IL-3months-3.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
you are here: HomeNewsIpcalabs
management interviews
Jump to
10 Results Found
  • Aim is to prevent rampant use of antibiotics: P Lilladher Mar 14, 2016 09:18 AM IST

    Aim is to prevent rampant use of antibiotics: P Lilladher

    Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

  • See India biz grow 15%, exports to rise 25% in H2: Ipca Oct 25, 2013 11:56 AM IST

    See India biz grow 15%, exports to rise 25% in H2: Ipca

    Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.

  • May revise guidance upwards post Q2: Ipca Labs Jul 30, 2013 04:11 PM IST

    May revise guidance upwards post Q2: Ipca Labs

    AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.

  • Indore facility to start production in 2 months: Ipca Labs Jun 06, 2013 04:58 PM IST

    Indore facility to start production in 2 months: Ipca Labs

    AK Jain, ED, Ipca Labs says the company's pain management segment is doing ver well and it has leadership in rheumatoid arthritis with substantial market share. The company's Indore facility will start production in 2 months.

  • Improvement in gross margins likely to continue: Ipca Labs Feb 04, 2013 01:11 PM IST

    Improvement in gross margins likely to continue: Ipca Labs

    Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.

  • Eyeing 18-20% growth in domestic market in FY13: Ipca Labs Apr 20, 2012 11:40 AM IST

    Eyeing 18-20% growth in domestic market in FY13: Ipca Labs

    Exectuive director of Ipca Labs AK Jain told CNBC-TV18 that Ipca Lanbs aims to grow by 18-20% in the domestic market in FY13.

  • Ipca Labs eyes 20% export growth in second half of FY12 Nov 01, 2011 03:56 PM IST

    Ipca Labs eyes 20% export growth in second half of FY12

    Executive Director of Ipca Labs AK Jain tells CNBC-TV18 that they aim to grow exports by 20% in the second half of the current fiscal year.

  • Ipca Labs hopes to achieve 18-20% growth for FY12 Sep 13, 2011 04:15 PM IST

    Ipca Labs hopes to achieve 18-20% growth for FY12

    AK Jain, the executive director of Ipca Labs, in an interview on CNBC-TV18, talks about the latest happenings in the company and sector.

  • Ipca Laboratories expects to clock 18-20% growth in FY12 May 25, 2011 01:26 PM IST

    Ipca Laboratories expects to clock 18-20% growth in FY12

    AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.

  • Expect USFDA nod for Indore unit in three months: Ipca Labs Mar 21, 2011 03:33 PM IST

    Expect USFDA nod for Indore unit in three months: Ipca Labs

    In an interview with CNBC-TV18, AK Jain, ED of Ipca Labs said, "We are waiting for the US FDA to inspect our SEZ Indore plant. This product will be produced there so, till the time we get the approval for the plant we will not be able to take the commercial production of this product."

Sections